The severe Ebola outbreak currently unfolding in the Democratic Republic of the Congo has exposed profound vulnerabilities in the architecture of global health security. While health institutions and international officials are intimately familiar with the pathogen—having first discovered it in northern Congo, then Zaire, in 1976—this epidemic has defied standard containment protocols. Over the past five decades, medical professionals and governments across the globe have honed their ability to diagnose the disease, track its transmission pathways, and halt its progress when caught early.
Yet, the ongoing epidemic, which has claimed more than 3,500 lives across Congo since the beginning of the year, has already established itself as the deadliest the country has ever recorded and the fastest-spreading in history. Despite recent, localized signs of medical progress, the outbreak remains stubbornly uncontained.
This failure to swiftly control the present Ebola crisis sends an ominous signal regarding the world’s capacity to confront future biological threats. Naturally occurring viruses are emerging with increasing frequency. During the four years of the Biden administration, health authorities recorded 12 outbreaks of Ebola and Marburg—another lethal disease belonging to the same viral family. This represented a substantial increase compared to the five outbreaks documented during the preceding four-year period. The current Trump administration faces an even steeper trajectory, having already contended with five distinct outbreaks in less than two years.
Compounding this natural surge is the escalating risk of an accidental or deliberate release of a deadly virus. The global research boom following the COVID-19 pandemic has led to a rising number of laboratories handling high-risk pathogens. At the same time, advancements in artificial intelligence have dramatically lowered the barrier for engineering novel viruses. Earlier this month, the American AI firm Anthropic disclosed five distinct cases in which researchers utilized its AI software, Claude, for inquiries that could support biological weapons development. This included experimenting with variants of bird flu designed to evade human immune systems. The disclosures confirmed long-standing fears that advanced AI models could inadvertently or intentionally assist bad actors in accessing hazardous biological materials.
Meanwhile, the global health infrastructure has experienced significant attrition, weakened in part by the Trump administration’s cuts to domestic and international disease surveillance and outbreak preparedness programs. However, systemic fragility predated these recent policy shifts. Global threat monitoring frameworks suffer from persistent gaps, inconsistent funding models routinely delay vaccine development, and the vast majority of nations severely underinvest in routine, comprehensive public health systems. While Washington and other international donors frequently mobilize substantial resources once a crisis erupts, scrambling to assemble an emergency response is a profoundly inefficient way to manage a biological threat. When a novel or lesser-known pathogen begins to spread, the global community requires a far more robust, proactive posture of preparedness.
THE CRISIS IN CONGO
The current outbreak in the Democratic Republic of the Congo likely originated at least eight months ago. Residents in Mongbwalu, a small community in the northeastern region of the country, reported entire families succumbing to a mysterious and rapid illness as early as January. The virus circulated undetected for months before the Congolese government, working in partnership with the World Health Organization, officially confirmed the source of the epidemic in mid-May. By that time, hundreds of infections had already been identified across multiple communities in Congo, and two cases had been verified across the border in Uganda.
While some delay in detection is understandable given the remote geography of the earliest deaths, ongoing regional conflict, and the relative rarity of the outbreak’s specific driver—the Bundibugyo virus—the unprecedented spread prior to detection indicates a systemic retrogression in global health preparedness.
Four months after the official confirmation, responders representing the Congolese government, the WHO, and the Africa Centres for Disease Control and Prevention continue to face immense difficulties in reining in the virus. The case fatality rate hovers around 50 percent, which is significantly higher than previous outbreaks driven by the Bundibugyo strain. Furthermore, data shows that 60 percent of deaths recorded between mid-July and late August occurred outside of formal health facilities. These patterns strongly suggest that the true burden of illness and mortality exceeds official figures, and that the pathogen continues to circulate beyond the reach of public health officials.
Although health authorities have reported minor markers of progress, WHO Director-General Tedros Adhanom Ghebreyesus has issued stark warnings. If the epidemic maintains its current epidemiological trajectory, the ultimate death toll could surpass that of the largest Ebola crisis in history—the West African epidemic of 2014 to 2016, which infected nearly 30,000 people and killed more than 11,000.
The withdrawal of the United States from the WHO and the subsequent dissolution of the U.S. Agency for International Development severely compromised the operational capacity of both international bodies and the Congolese government. Nicholas Enrich, a career civil servant who briefly directed USAID’s global health portfolio during the early months of the Trump administration, detailed in his book Into the Wood Chipper his efforts to persuade politically appointed USAID leadership to reinstate contracts for Ebola response initiatives. Those contracts had been canceled amid an earlier outbreak in Uganda that began in January 2025.
Although the Trump administration maintained that these vital programs were ultimately resumed, former USAID implementing partners—including the International Rescue Committee and Oxfam—publicly confirmed that Washington terminated its funding for health programs in eastern Congo in 2025.
Concurrently, the administration dismissed the majority of USAID’s health security personnel, dissolved a specialized National Security Council biodefense team established in the wake of the 2014 West African crisis, and left the leadership role at the White House Office of Pandemic Preparedness and Response Policy vacant for an entire year. Thousands of staff positions at the U.S. Centers for Disease Control and Prevention were also eliminated, including entire branches within the agency’s Global Health Center. Furthermore, the CDC was formally prohibited from communicating directly with the WHO. Following these sweeping reductions and institutional restrictions, the Ebola virus was permitted to circulate for four months before U.S. experts or allied organizations could sound the alarm.
The White House has consistently defended its actions, arguing that administrative cuts have not hindered the detection or containment of the virus. In May, a White House spokesperson asserted that USAID reductions had rendered the "entire global health apparatus more efficient and responsive."
Nevertheless, public health analysts find it difficult to reconcile the closure of offices, the termination of experienced government personnel, and the severing of disease surveillance partnerships with the reality of an escalating epidemic. In recent months, Washington has scrambled to bridge the gaps created by its earlier budget cuts by filling vacant posts and committing more than $500 million in emergency assistance to the Ebola response—surpassing the financial contributions of any other nation. Yet, emergency infusions of cash remain substantially more expensive and demonstrably less effective when the underlying health infrastructure has already been degraded by sustained aid reductions.
A STRUGGLING SYSTEM
Perhaps more alarming than the withdrawal of American support is a broader collection of structural failures within the global health architecture. Catching an outbreak during its initial days or weeks is essential for rapid containment, but the current crisis has demonstrated that existing early-warning processes are fundamentally inadequate. For decades, health workers have relied heavily on pathogen-specific tests deployed in known high-risk zones, such as testing for traditional Ebola strains in Congo or hantavirus in Argentina.
This narrow diagnostic model was bound to experience failure. Public health officials in northeastern Congo possessed Ebola diagnostic tools earlier this year, but those tests were not engineered to detect the Bundibugyo species. This variant-specific blind spot will not be the last of its kind as viruses continue to mutate and infected travelers cross international borders into less monitored territories. Merely scaling up the production of existing, narrow-spectrum tests is not a viable solution, as these diagnostic tools are often costly and demand specialized training for administration.
Once the virus began to spread within Congo, government officials and non-governmental organization responders should have been positioned to collaborate closely with affected populations. Instead, deep-seated community distrust and fear have sparked hundreds of security incidents targeting health workers and medical facilities, severely impeding the ability of response teams to identify infected individuals and halt transmission chains. These obstacles are entirely predictable against a backdrop of chronic neglect. Millions of Congolese citizens were already grappling with high burdens of malaria, measles, and severe malnutrition; malaria alone claimed more than 20,000 lives in 2024.
Resources from high-income nations and multilateral institutions typically fail to materialize until an international threat like Ebola breaches local communities. This historical pattern breeds justified skepticism toward international interventions that focus exclusively on headline-grabbing pathogens while ignoring endemic crises. This relative neglect creates practical complications as well: because early symptoms of Ebola, such as high fever, closely mirror those of common endemic illnesses, many residents delay seeking medical care until they are critically ill, thereby elevating their personal risk of mortality and widening the window for viral transmission.
Regional insecurity has further paralyzed containment operations. Eastern Congo has experienced persistent armed conflict for decades, and fighting along the borders of Uganda and Rwanda has intensified significantly over recent years. An estimated nine million Congolese citizens have been internally displaced, with many fleeing to neighboring nations or overcrowded camps lacking basic water, sanitation, and medical infrastructure. These encampments are already battling high rates of malaria, measles, and cholera, creating a dangerous breeding ground for potential Ebola transmission.
Concurrently, ongoing violence places public health workers in extreme peril and disrupts supply chains heading into northeastern region. While political leaders acknowledge that insecurity impedes public health progress, experts emphasize that until long-term peace is achieved, health systems require resilient operational tools. These include secure supply transport protocols, stockpiles of personal protective equipment, robust partnerships with trusted local leaders to disseminate accurate health messaging, and sustained investments in basic sanitation infrastructure for displaced populations.
One of the few encouraging developments in the ongoing crisis has been the comparatively rapid advancement of vaccine candidates targeting the Bundibugyo virus. The first experimental vaccine dose was administered in a Phase 1 clinical trial within 12 weeks of the outbreak’s official confirmation—representing twice the speed achieved during the 2014 West African crisis. This acceleration was largely enabled by long-term financial investments from the U.S. and Europe into institutions like the Coalition for Epidemic Preparedness Innovations, a public-private partnership, alongside facilities such as the Uganda Virus Research Institute. These entities had pre-positioned research materials, established modern laboratories, and cultivated regional scientific partnerships designed to be activated during a public health emergency.
Despite this relative speed, months remain before these novel vaccines can be deployed for broader public inoculation. Immediate containment continues to rely entirely on traditional public health interventions, including rigorous contact tracing and isolation, which demand vast, well-coordinated response teams. Vaccine development pipelines must accelerate further, yet the prevailing global health funding model relies on crisis-driven financing rather than sustained prophylaxis. While researchers possessed the foundational capacity to design and test vaccines for the Bundibugyo virus prior to the current epidemic, they lacked the requisite funding and sustained political backing to finalize them proactively.
FILLING IN THE GAPS
The resurgence of Ebola has starkly illuminated systemic deficiencies in humanity’s preparedness for predictable health emergencies, raising profound concerns about how the international community would manage a far more complex biological threat. Last month, a study published in the journal Science confirmed the first successful synthesis of a complete, functional viral genome utilizing artificial intelligence. With bad actors potentially capable of engineering bespoke pathogens designed to evade human immunity and existing medical countermeasures, the stakes for global security have never been higher.
This crisis must serve as an urgent catalyst, mirroring the awakening that followed the West African Ebola epidemic a decade ago. That historic crisis spurred the United States and international partners to invest heavily in research and development, yielding life-saving vaccines that have since suppressed subsequent outbreaks. It compelled Washington to establish specialized domestic biodefense infrastructure and prompted the African Union to launch the Africa CDC in 2017, fundamentally enhancing the continent’s capacity to manage regional health threats.
Governments, private industry, and multilateral institutions now possess a parallel opportunity to reinforce global health security. Technological innovation offers a clear path forward. Some of the same technological advances increasing biosecurity risks also empower nations to build sophisticated national surveillance systems capable of identifying known and unknown biological threats in real time, while accelerating the creation of countermeasures.
The U.S. government possesses the financial resources and strategic incentives to develop such a domestic early warning system within the coming years, which could eventually be scaled globally through international burden-sharing agreements. While geopolitical complications—such as China’s historical reluctance to share complete epidemiological data regarding the origins of COVID-19—may impede universal participation, establishing a comprehensive monitoring network covering the majority of the globe would still represent a massive improvement over current monitoring frameworks.
Simultaneously, vaccine research demands enhanced capital investment and steadfast political commitment. Organizations like CEPI are pioneering platform technologies targeting entire viral families, allowing scientists to rapidly adapt medical countermeasures when a specific pathogen emerges. However, these efforts require sustained financial backing.
The World Bank and the WHO estimate that approximately $10.5 billion in annual international financing is necessary to sustain a comprehensive global pandemic preparedness and response system, with roughly $2 billion dedicated specifically to research, development, and supply access. While substantial, this investment pales in comparison to the economic devastation wrought by uncontrolled pathogens; the COVID-19 pandemic alone cost the U.S. economy an estimated $14 trillion.
Governments must spearhead cross-border collaboration to streamline regulatory frameworks, coordinate manufacturing capacity, and establish transparent information-sharing protocols, while partnering with technology firms to harness AI for accelerated vaccine design.
Finally, the international health architecture requires a clearer division of labor among local, regional, and multilateral institutions. National governments must take primary responsibility for protecting local populations from endemic burdens like malaria and measles. Regional bodies, such as the Africa CDC, which maintain greater accountability to national governments than distant global agencies, should oversee cross-border surveillance and communication networks. At the multilateral level, the WHO must refocus squarely on its core mandate: providing technical guidance on cross-border health threats and coordinating international outbreak responses, rather than spreading its limited personnel and budget across an unmanageable array of global health issues.
The prevailing ad hoc system remains overly dependent on the United States to mobilize personnel and resources during every acute emergency. It has struggled to contain the current Ebola outbreak, and it faces an uncertain future when a far less familiar pathogen inevitably emerges. Building a resilient global health infrastructure is an urgent imperative that cannot wait until the next crisis arrives.
